Compare · Head-to-head
MGF E-domain vs TB-500.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with TB-500, then use the table to confirm fit.
TB-500 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
MGF E-domain
IGF-1 splice variant peptide studied preclinically for muscle repair signaling.
01 · At a glance
| Decision factor | MGF E-domain | TB-500 |
|---|---|---|
| Primary fit | muscle growth & strength and tissue repair & recovery comparisons | tissue repair & recovery research where you want a clear starting point |
| Evidence | Tier C | Tier C |
| Risk | extreme | med-high |
| Experience level | advanced | intermediate |
| Budget tier | mid | mid |
| Administration route | subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | MGF E-domain | TB-500 |
|---|---|---|
| Goal fit | Muscle Growth & Strength, Tissue Repair & Recovery | Tissue Repair & Recovery |
| What users compare it for | Muscle repair signaling in preclinical models. | Soft-tissue repair and recovery signals in preclinical models. |
| Onset timeline | Preclinical outcomes vary by model. | Preclinical: varies by injury model. Consumer timelines are speculative. |
| Main tradeoff | Potential upside comes with much more safety and screening caution than lower-risk alternatives. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | MGF E-domain | TB-500 |
|---|---|---|
| Adverse effects | Limited data; growth-factor class concerns apply. | Limited safety data; sequence ambiguity adds quality risk. |
| Contraindications | No human data. | No established contraindications (insufficient data). |
| Interaction notes | Unknown. | Unknown/insufficient. Caution when combining with full-length thymosin beta-4 due to sequence overlap. |
| Regulatory status | Not approved | Not approved |
| FDA flag | FDA status unclear | FDA status unclear |
| WADA status | WADA S2 | WADA S2 |
04 · Age & monitoring
| Decision factor | MGF E-domain | TB-500 |
|---|---|---|
| Supported age ranges | No age guidance yet | 25-34, 35-44, 45-54, 55-64 |
| Life-stage note | Not yet documented | Usually framed as a recovery compound for active adults rather than a later-life maintenance tool. |
| Monitoring burden | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | MGF E-domain | TB-500 |
|---|---|---|
| Typical cycle cost | No reliable estimate yet | $287.97 |
| Estimated monthly cost | No reliable estimate yet | $143.98 |
| Cost confidence | No estimate | High confidence |
06 · Before you buy
| Decision factor | MGF E-domain | TB-500 |
|---|---|---|
| Tracked vendor listings | 0 listings | 3 listings |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.